Kinomica secures £3.9m in seed funding led by BGF and Longwall Venture Partners to scale operations.
The seed round was co-led by BGF and Longwall Venture Partners with participation from seed backers including BioCity, Alderley Park Ventures, and Puffin Point.
Kinomica is a proteomic data science and diagnostics company that develops pioneering cell signalling bioinformatics and biomarker platforms for precision medicine. Headquartered in Alderley Park, the business provides innovative tools to aid the development of kinase inhibitor drugs and cancer treatments.
Proteomic data science specialist Kinomica has secured £3.9m in a seed funding round led jointly by BGF and Longwall Venture Partners. Additional capital was provided by seed investors including BioCity, Alderley Park Ventures, and London family office Puffin Point. The fresh injection of capital will be directed towards scaling up operational facilities and equipment to support a growing pipeline of projects.
Kinomica intends to leverage its proprietary KScan platform to accelerate the development of kinase inhibitor drugs and improve patient stratification for clinical trials. The company has already established commercial partnerships with major pharmaceutical firms such as AstraZeneca. The latest financing marks a significant milestone as the firm pursues its ambition of becoming a global leader in cell signalling bioinformatics.
From the founder
"This marks a huge step forward for Kinomica and for KScan™, as we look to the future of cancer treatment. Our pioneering technology offers much-needed support for the development of new precision medicines and represents a new approach to drug trials and treatments that will have a huge impact on patients’ lives."
Jane Theaker
CEO at Kinomica
Investor perspective
"Kinomica is a phenomenal example of early-stage life sciences innovation emerging from the UK. The business’ technology has the potential to provide insights to its pharma customer-base which help to identify drug targets, personalise treatments and develop diagnostics, that will transform patient outcomes."
Rhys Davenport
Investor, BGF
Use of funds
- 01Scale operations
Investors
Rhys Davenport
BGF
Rebecca Todd
Longwall Venture Partners
BioCity
Alderley Park Ventures
Puffin Point